Soft tissue XXXX (excluding rhabdomyosarcoma): radiotherapy applications.

@entity1 @entity242 @entity1161 @entity5 @entity1492 @entity6011
@entity1161 ( @entity1161 ) is a highly effective modality in the treatment of @entity242 of soft tissue when combined with conservative surgery. @entity1161 followed by surgery is judged to have important clinical advantages over the reverse sequence. Of special significance to the treatment of the pediatric @entity1 is the observation that the treatment volume in preoperative @entity1161 is nearly always smaller than in postoperative @entity1161 . Precise definition of the target volume and utilization of minimum treatment volumes (i.e., reduction of the treatment volume toward the target volume to the greatest extent technically feasible) are particularly important to the improvement of functional results. Data are described for 21 @entity1 who were 21 years old or younger and were treated by @entity1161 and surgery and @entity1161 alone and who have been followed for 3 or more years. Local control of the treated @entity5 was achieved in all 21. Absolute figures for disease-free survival were 5 of 5 and 10 of 16 @entity1 in the 6- to 14- and 15- to 21-year age groups, respectively. Survival results according to stages for the latter group were as follows: stage I, 4 of 4; stage II, 4 of 7; and stage III, 2 of 5. All 9 @entity1 with @entity1492 or @entity6011 survived free of disease. The need for an effective chemotherapy regimen for @entity1 in stages IIB--III is emphasized.
